Telomerase expression in intracranial tumours: prognostic potential for malignant gliomas and meningiomas

Maria Laura Falchetti, Roberto Pallini, Luigi M Larocca, Roberto Verna, Ettore D’Ambrosio

Abstract

**Aim**—To evaluate the diagnostic value of telomerase expression in intracranial tumours.

**Methods**—98 surgical specimens from different neoplasms were analysed by the telomeric repeat amplification protocol (TRAP) and the presence of telomerase compared with the histological diagnosis and the proliferation index.

**Results**—A high degree of positivity for telomerase activity was found in glioblastomas and atypical/anaplastic meningiomas. Telomerase activity was poorly detected in anaplastic astrocytomas.

**Conclusions**—The TRAP assay seems to be a valuable index for identifying meningial tumours with aggressive behaviour.

Keywords: intracranial tumours; telomerase; TRAP

The term telomere refers to the extreme ends of eukaryotic chromosomes which are composed of tandem repeated short sequences associated with specific proteins. These structures protect the chromosomes from degradation and prevent them from fusing with each other and from recombining with internal DNA. Owing to the incapacity of DNA polymerase to replicate the very end of linear DNA, other and from recombining with internal chromosomes,1 telomeres shorten at each cell division in somatic cells. In contrast, in germ line cells, telomere length is maintained by the activity of telomerase, a ribonucleoprotein complex which adds the human telomeric TTAGGG repeat to the chromosome ends. The enzymatic activity of telomerase is strictly regulated. In human somatic cells of different lineages, it is not detectable and telomere length decreases with increasing number of cell divisions in vitro and with age in vivo. Reactivation of telomerase seems to be related to unrestrained cell proliferation and cancer progression.2 Mutations may occur that reactivate telomerase and stabilise telomere length by the addition of telomeric repeats, allowing unlimited proliferation. Using the highly sensitive telomeric repeat amplification protocol (TRAP) method,3 various human cancers have been analysed and a good correlation shown between telomerase activity and tumour malignancy.4,5 In some cases, telomerase activity has also given valuable information on prognosis; for example, high levels of telomerase are associated with a poor outcome in neuroblastomas and gastric cancer.6,7 In order to evaluate the diagnostic value of the TRAP assay and to gain a better understanding of the role of telomerase in cell immortalisation, we analysed a series of intracranial tumours and compared the results of the TRAP assay with histological diagnosis and proliferative index.

**Methods**

Tissue specimens were obtained from 98 patients who underwent surgery for resection of intracranial tumours. Clinical features of patients are summarised in table 1. No procedures were performed for research purposes only. The tumours were classified for histology according to the World Health Organisation criteria.7 The proliferative index was calculated as the percentage of tumour cell nuclei immunoreactive for Ki 67 to total tumour nuclei. In each specimen we studied at least 500 neoplastic cells, as defined by histological criteria. For telomerase analysis, the surgical specimens were immediately frozen in liquid nitrogen and stored at −80°C until use. Protein extracts were prepared using CHAPS containing extraction buffer as described by Hiyama et al.,1 and protein concentration was determined with BCA protein assay reagent (Pierce). An amount of 2 µg of protein was used for telomerase assays. The samples were analysed using a modified TRAP test.6 Briefly, we redesigned the downstream primer CX to minimise the possibility of primer dimer interaction, resulting in improved sensitivity and reproducibility of the test as compared with the original TRAP protocol.

**Results**

Results are shown in table 2. Our series consisted mainly of astrocytic tumours (45 cases) and meningial tumours (31 cases). There were 11 recurrent tumours including three glioblastomas, one anaplastic astrocytoma, five anaplastic/typical meningiomas, one haemangioblastoma, and one ependymoma.
Table 2  Telomerase expression in intracranial tumours

<table>
<thead>
<tr>
<th>Histology (WHO grade)</th>
<th>n</th>
<th>Telomerase activity</th>
<th>Proliferative index, mean (min-max)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Positive (%)</td>
<td>Negative (%)</td>
</tr>
<tr>
<td>Neuroepithelial and meningeal tumours</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Astrocytic tumours</td>
<td>45</td>
<td>4 (0)</td>
<td>31 (100)</td>
</tr>
<tr>
<td>Anaplastic astrocytoma (III)</td>
<td>11</td>
<td>3 (27.3)</td>
<td>8 (72.7)</td>
</tr>
<tr>
<td>Glioblastoma (IV)</td>
<td>30</td>
<td>25 (83.3)</td>
<td>5 (16.6)</td>
</tr>
<tr>
<td>Oligodendrogliomas</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Oligodendrogioma (II)</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Other neuroepithelial tumours</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroid plexus papilloma (I)</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Pineoblastoma (IV)</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Neuroblastoma (IV)</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Meningeal tumours</td>
<td>31</td>
<td>21 (0)</td>
<td>21 (100)</td>
</tr>
<tr>
<td>Meningioma (I)</td>
<td>21</td>
<td>6 (75)</td>
<td>2 (25)</td>
</tr>
<tr>
<td>Anaplastic meningioma (III)</td>
<td>2</td>
<td>2 (100)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Other tumours</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miscellaneous tumours</td>
<td>16</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Chondrosarcoma</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Craniopharyngioma</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Epidermoid cyst</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Pituitary adenoma</td>
<td>8</td>
<td>2 (25)</td>
<td>6 (75)</td>
</tr>
<tr>
<td>Cavernous angioma</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Haemangioblastoma</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

*Diffuse large B cell lymphoma according to the REAC classification.*

Cyst. Two of the recurrent glioblastomas had a previous diagnosis of anaplastic astrocytoma. In the other recurrent tumours, histology was unchanged at reoperation.

Overall, telomerase activity was detected in 43 cases (43.9%). The highest degree of telomerase activity was found in glioblastomas and atypical/anaplastic meningiomas (fig 1). It seems that astrocytic tumours show increasing percentages of telomerase positivity with tumour progression toward malignancy. A similar correlation was observed in meningeal tumours. Telomerase activity was detected in 25 of 30 glioblastomas (83.3%). By contrast, only three of 11 anaplastic astrocytomas (27.3%) had a positive telomerase reaction. This discrepancy in the presence of telomerase was not associated with a marked difference in the proliferative index, which averaged 19.8% and 23.2% in the glioblastomas and anaplastic astrocytomas, respectively. In addition, we did not find a significant difference in the proliferative index between glioblastomas with a positive telomerase reaction and those with a negative reaction (p > 0.05, Student t test).

On the basis of the clinical data and histology from previous surgery, three glioblastoma cases could be considered secondary tumours. Two of them showed a positive telomerase reaction, while the third was negative. The presence of polymerase chain reaction or Taq inhibitors in negative TRAP reactions seems unlikely because negative extracts retested in the presence of an internal DNA standard remained negative, while the internal DNA standard was easily amplified (data not shown).

**Discussion**

The different telomerase pattern between glioblastomas and anaplastic astrocytomas, which has also been reported by others, is intriguing. Most of glioblastomas are thought to arise by progression of anaplasia from pre-existing astrocytomas. Because of the heterogeneous nature of anaplastic astrocytomas it is possible that the astrocytoma samples used for telomerase analysis, though including a proliferating cell population as demonstrated by the Ki 67 labelling index, missed the anaplastic foci. Alternatively, it is possible that in anaplastic astrocytomas the mechanisms of DNA replication do not involve telomerase, a conclusion that would favour the concept that glioblastomas represent a primary cancer of the brain. In meningeal tumours, all the WHO grade I meningiomas were found to be negative for telomerase activity, whereas six of eight atypical meningiomas (WHO grade II) and both cases of anaplastic meningioma (WHO grade III) showed telomerase activity (table 2 and fig 1). Although the small number of atypical/anaplastic meningiomas does not allow definitive conclusions to be drawn, the present work and a similar study indicate that telomerase detection may help in differentiating benign meningiomas from meningiomas with aggressive biological behaviour, whereas conventional histology may not be conclusive.

The other tumours from our study (table 2) formed a heterogeneous group of neoplasms and only limited conclusions can be drawn. The overall picture emerging from this miscellaneous group of intracranial tumours is that telomerase cannot be considered a specific feature of tumour malignancy, since it was detected both in highly malignant tumours, such as a pineoblastoma and a lymphoma, and also in benign tumours, such as pituitary adenomas and a choroid plexus papilloma. Conversely, telomerase was lacking in a malignant neuroblastoma and a chondrosarcoma. It has been suggested that in some neuroblasto-
mas which do not show telomerase activity, the
telomeres might eventually reach a critically
shortened length, with the tumour undergoing
spontaneous remission.4

In conclusion, our study shows that the
assessment of telomerase activity may influ-
ence tumour prognosis, and possibly treat-
ment, in malignant gliomas and meningiomas.
Telomerase analysis may also be a valuable
contribution in the differential diagnosis of
glioblastoma and anaplastic astrocytoma, and
in the detection of the atypical meningiomas.
The large number of telomerase negative
intracranial tumours implies that alternative
mechanisms to stabilise telomeres may be
present. Importantly, the discordance observed
between telomerase activity and proliferation
index suggests that telomerase may be a novel
marker for brain cancer.

References
1 Watson JD. Origin of concatameric T7 DNA. Nature New
2 Kim NW, Piatyszek MA, Prowse K, et al. Specific
association of human telomerase activity with immortal
3 Avilion AA, Piatyszek MA, Gupta J, et al. Human telomer-
ase RNA and telomerase activity in immortal cell lines and
4 Hiyama E, Hiyama K, Yokoyama T, et al. Correlating
telemerase activity levels with human neuroblastoma
5 Hiyama E, Yokoyama T, Satomoto N, et al. Telomerase
6 Langford LA, Piatyszek MA, Xu R, et al. Telomerase activ-
7 Kleihues P, Burger PC, Scheithauer BW. The new WHO
and reproducibility of TRAP assay by avoiding direct
9 Harris NL, Jaffe ES, Stein H, et al. A revised
European–American classification of lymphoid neoplasms:
a proposal from the international lymphoma study group.
10 Langford LA, Piatyszek MA, Xu R, et al. Telomerase activ-
ity in ordinary meningiomas predicts poor outcome. Hum